Antibodies

07 Mar 2017 FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine
04 Mar 2017 LEO Pharma Announces Positive Results From Phase 2b Clinical Study for Tralokinumab in Atopic Dermatitis
04 Mar 2017 Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
03 Mar 2017 New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis
02 Mar 2017 Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
02 Mar 2017 BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
02 Mar 2017 Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy
28 Feb 2017 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
28 Feb 2017 AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
28 Feb 2017 Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies
28 Feb 2017 Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
24 Feb 2017 Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncol
24 Feb 2017 DARZALEX®▼ (daratumumab) Receives Positive CHMP Opinion for the Treatment of Multiple Myeloma in Patients who have Received At Least One Prior Therapy
23 Feb 2017 MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer
23 Feb 2017 Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies
23 Feb 2017 CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium
23 Feb 2017 MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property at Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium
23 Feb 2017 New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease
22 Feb 2017 Atreca, Inc. Presents New Preclinical Findings for Novel Cancer Immunotherapy Platform at Molecular Medicine Tri-Conference 2017
22 Feb 2017 Truxima™, the first biosimilar mAb in oncology, granted EU marketing authorisation
22 Feb 2017 Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
21 Feb 2017 Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration
20 Feb 2017 New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs
18 Feb 2017 Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma
17 Feb 2017 New Data Shows STELARA® (ustekinumab) Maintained Clinical Response and Remission after Two Years of Treatment in Patients with Moderate to Severe Crohn’s Disease

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top